EGFL6 predicted the poor prognosis in patients with ACC, KIRC, LIHC, PAAD, THCA, and UCEC (P < 0.05), whereas EGFL7 predicted poor prognosis in the patients with COAD, KIRP, and MESO (P < 0.05). Here, EGFL6 is linked to pancreatic adenocarcinoma.